5alpha-Reductase inhibitors for prostate-cancer prevention.

摘要

to the editor: The decision by the Food and Drug Administration (FDA) not to approve the use of 5a-reductase inhibitors as a means of preventing prostate cancer, as discussed by Theoret et al. Quly 14 issue), illustrates the challenges that thwart efforts to develop agents for this purpose. To support its position, the FDA reanalyzed two major trials.